Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pfaller

Showing results (331-340 of 542) with videos related to

Pageof 55
Sort By:
American Journal of Clinical Pathology|January 1, 1988
Evaluation of laboratory methods for the classification of oxacillin-resistant and oxacillin-susceptible Staphylococcus aureusM A Pfaller, D S Wakefield, B Stewart, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1982
Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complexC D Fitch, R Chevli, H S Banyal, et al.
Journal of Clinical Microbiology|October 7, 2005
Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance programM A Pfaller, L Boyken, S A Messer, et al.
Journal of Clinical Microbiology|August 6, 2005
In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsM A Pfaller, L Boyken, R J Hollis, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2000
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformansT Yamazumi, M A Pfaller, S A Messer, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1995
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patientsF Barchiesi, R J Hollis, S A Messer, et al.
Journal of Clinical Microbiology|December 21, 2007
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance programM A Pfaller, S A Messer, L Boyken, et al.
Diagnostic Microbiology and Infectious Disease|October 12, 2004
Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformansM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|July 10, 2004
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002M A Pfaller, S A Messer, L Boyken, et al.
Journal of Clinical Microbiology|September 1, 1994
High frequency of yeast carriage on hands of hospital personnelL J Strausbaugh, D L Sewell, T T Ward, et al.
Pageof 55

Showing results (331-340 of 542) with videos related to

Sort By:
Pageof 55
American Journal of Clinical Pathology|January 1, 1988
Evaluation of laboratory methods for the classification of oxacillin-resistant and oxacillin-susceptible Staphylococcus aureusM A Pfaller, D S Wakefield, B Stewart, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1982
Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complexC D Fitch, R Chevli, H S Banyal, et al.
Journal of Clinical Microbiology|October 7, 2005
Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance programM A Pfaller, L Boyken, S A Messer, et al.
Journal of Clinical Microbiology|August 6, 2005
In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsM A Pfaller, L Boyken, R J Hollis, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2000
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformansT Yamazumi, M A Pfaller, S A Messer, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1995
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patientsF Barchiesi, R J Hollis, S A Messer, et al.
Journal of Clinical Microbiology|December 21, 2007
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance programM A Pfaller, S A Messer, L Boyken, et al.
Diagnostic Microbiology and Infectious Disease|October 12, 2004
Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformansM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|July 10, 2004
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002M A Pfaller, S A Messer, L Boyken, et al.
Journal of Clinical Microbiology|September 1, 1994
High frequency of yeast carriage on hands of hospital personnelL J Strausbaugh, D L Sewell, T T Ward, et al.
Pageof 55